ChromaDex (NASDAQ:CDXC) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of ChromaDex (NASDAQ:CDXC) from a strong-buy rating to a buy rating in a research report sent to investors on Wednesday morning.

Several other analysts have also issued reports on the company. Roth Mkm upped their target price on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. HC Wainwright upped their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 4th.

ChromaDex Trading Up 6.3 %

NASDAQ:CDXC opened at $5.77 on Wednesday. ChromaDex has a 1 year low of $1.36 and a 1 year high of $7.97. The stock has a market cap of $440.73 million, a price-to-earnings ratio of 577.58 and a beta of 2.21. The stock has a 50-day moving average price of $6.38 and a two-hundred day moving average price of $4.41.

ChromaDex (NASDAQ:CDXC) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. The company had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same period in the prior year, the firm earned ($0.01) earnings per share. Sell-side analysts forecast that ChromaDex will post 0.04 earnings per share for the current year.

Insider Buying and Selling at ChromaDex

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the sale, the director now owns 244,179 shares in the company, valued at $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 9.64% of the company’s stock.

Hedge Funds Weigh In On ChromaDex

Large investors have recently made changes to their positions in the company. USA Financial Formulas bought a new position in shares of ChromaDex during the fourth quarter worth approximately $25,000. The Manufacturers Life Insurance Company bought a new position in shares of ChromaDex during the second quarter worth approximately $31,000. Merriman Wealth Management LLC bought a new position in shares of ChromaDex during the second quarter worth approximately $32,000. FMR LLC bought a new position in shares of ChromaDex during the third quarter worth approximately $55,000. Finally, Marshall Wace LLP bought a new position in shares of ChromaDex during the second quarter worth approximately $56,000. Institutional investors own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.